Bionexus Gene LabBGLC
13F holders, Q2 2024 (June 30)3holders −1
0new positions
1sold out
$0.46avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were Virtu Financial LLC ($13K), Geode Capital Management, LLC ($11K) and HRT Financial LP ($6K).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628207
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $6K |
All 13F filers, Q1 2024 → Q2 2024: 35,314 shares sold, net −35,314 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Virtu Financial LLC | 0.00% | Reduce -41.8% | 27,372 | $13K |
| Geode Capital Management, LLC | 0.00% | No change | 23,681 | $11K |
| HRT Financial LP | 0.00% | Reduce -33.0% | 14,672 | $6K |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.